Abstract:
OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regarding HRQL measured by the St. George's respiratory questionnaire (SGRQ) are presented. The total population was divided into two subgroups, high and Low SGRQ, using the median of the total SGRQ score. Univariate analysis and logistic regression analysis with calculation of adjusted odds ratios were used to investigate the factors significantly associated with a higher SGRQ score (poor HRQL). RESULTS:A total of 27 investigators included 222 valid patients with a mean age of 68.2 years (SD = 9.9) and a mean FEV1(%) of 49.2% (SD = 15.4%). The median total SGRQ score was 39.5 and patients with a high score had a longer evolution of COPD (p < 0.0001), more severe dyspnea (p < 0.0001) and a worse FEV1(%) (46.3% vs. 51.9%; p = 0.008). Factors independently associated with the total SGRQ score were cough and dyspnea, duration of COPD and treatment with inhaled steroids. CONCLUSION:: Patients with COPD controlled in primary care demonstrate an important impairment in HRQL, with chronic cough and dyspnea being associated with more impaired HRQL. Strategies aimed at modifying these factors should significantly improve the well-being of COPD patients.
journal_name
Ther Adv Respir Disjournal_title
Therapeutic advances in respiratory diseaseauthors
Miravitlles M,Molina J,Naberan K,Cots JM,Ros F,Llor C,EVOCA study.doi
10.1177/1753465807086097subject
Has Abstractpub_date
2007-12-01 00:00:00pages
85-92issue
2eissn
1753-4658issn
1753-4666pii
1/2/85journal_volume
1pub_type
杂志文章,多中心研究abstract::Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β2-adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients' d...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466618760779
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initiating treatment, especially when IPF patients have stable dise...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620953783
更新日期:2020-01-01 00:00:00
abstract:OBJECTIVES:This study evaluated the effectiveness of behavioral interventions (brief counseling, nonspecific psychological support in groups - NSGS and cognitive behavioral group therapy - CBGT) in combination with bupropion SR for smoking cessation in the field, through a smoking cessation clinic. METHODS:Two-hundred...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,随机对照试验
doi:10.1177/1753465809350653
更新日期:2009-12-01 00:00:00
abstract::Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Inflammation is the most important component of asthma and inhaled corticosteroids (ICS) are recommended as the first line controller treatment for patients of all ages. Treatment with corticosteroids ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465809348014
更新日期:2009-10-01 00:00:00
abstract::Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although re...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466618794133
更新日期:2018-01-01 00:00:00
abstract::Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe g...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466620926800
更新日期:2020-01-01 00:00:00
abstract::Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465812444712
更新日期:2012-08-01 00:00:00
abstract:BACKGROUND:It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma. METHODS:Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted acco...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620981863
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:N-chlorotaurine (NCT), a long-lived oxidant produced by human leukocytes, can be synthesized chemically and used topically as a well-tolerated antiseptic to different body regions including sensitive ones. The aim of this study was to test the tolerability of inhaled 1% NCT in aqueous solution upon repeated ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1177/1753466618778955
更新日期:2018-01-01 00:00:00
abstract::Angiogenesis is a driving force of a tumor's development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and m...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465815579608
更新日期:2015-08-01 00:00:00
abstract::There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465813503029
更新日期:2013-12-01 00:00:00
abstract:BACKGROUND:Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is well known as a life-threatening condition during its clinical course. However, the clinical features and prognosis in AE of unclassifiable idiopathic interstitial pneumonia (AE-UCIIP) remain to be elucidated. The aim of this study was to clarif...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620935774
更新日期:2020-01-01 00:00:00
abstract:OBJECTIVE:Our aim was to determine the influence of pulmonary rehabilitation conducted in therapeutic salt mine chambers on the functional fitness of older adults. METHODS:The study included 22 individuals of age >65 years with chronic respiratory conditions. The patients underwent the Fullerton test before and after ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620926952
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted t...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466618760133
更新日期:2018-01-01 00:00:00
abstract::COPD may be characterized by significant changes in airway mucosal blood vessels, which may contribute to bronchial airway remodeling. The airway wall is more vascularized in COPD patients than in healthy subjects, though this phenomenon is less evident than in asthmatic patients. The vascular mucosal changes in the a...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465808092339
更新日期:2008-06-01 00:00:00
abstract:BACKGROUND:Comorbidities probably contribute to the increased mortality observed among subjects with chronic obstructive pulmonary disease (COPD), but sex differences in the prognostic impact of comorbidities have rarely been evaluated in population-based studies. The aim of this study was to evaluate the impact of com...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466619860058
更新日期:2019-01-01 00:00:00
abstract:BACKGROUND:Disease severity may change in the first week after acute respiratory distress syndrome (ARDS) onset. The aim of this study was to evaluate whether the reclassification of disease severity after 48 h (i.e. day 3) of ARDS onset could help in predicting mortality and determine factors associated with ARDS pers...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620936877
更新日期:2020-01-01 00:00:00
abstract::Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy. Systemic prostacy...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465812455368
更新日期:2012-10-01 00:00:00
abstract:OBJECTIVE:The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of i...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753465813476564
更新日期:2013-08-01 00:00:00
abstract::Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465816669662
更新日期:2017-01-01 00:00:00
abstract::Allergen-specific immunotherapy remains the most likely effective treatment modality for allergic disorders by targeting the underlying immune mechanisms and possibly causing modifications in the disease course, as well as treating the symptoms. Treatment and compliance experiences been gained over nearly a century in...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465809349522
更新日期:2009-10-01 00:00:00
abstract::In recent years in the management of pulmonary arterial hypertension (PAH), endothelin receptor antagonists (ERAs) represent a well-established class of therapeutic agents with clear beneficial effects. Macitentan (Opsumit®), a dual ERA optimized for efficacy and safety, is the newest drug in the class. Macitentan pre...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753465814530182
更新日期:2014-06-01 00:00:00
abstract::Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465810387810
更新日期:2011-02-01 00:00:00
abstract:BACKGROUND:Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the results of eradicating Pa with tobramycin...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620905279
更新日期:2020-01-01 00:00:00
abstract::A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synth...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465808088903
更新日期:2008-04-01 00:00:00
abstract::Background We wanted to determine the impact of combined Clinical Pulmonary Infection Score (CPIS) and a spot serum procalcitonin (PCT)-guided protocol to shorten the duration of antibiotic treatment in patients with ventilator-associated pneumonia (VAP), mainly caused by nonfermentative gram-negative bacilli (NF-GNB)...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466618760134
更新日期:2018-01-01 00:00:00
abstract::To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465809103737
更新日期:2009-04-01 00:00:00
abstract:RATIONALE:Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with different levels of symptom severity. This study compared treatment responses ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620968500
更新日期:2020-01-01 00:00:00
abstract::Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different extrarticular manifestations involving heart, lungs and kidneys. In recent years there has been a growing awareness of the central role played by the lungs in the onset and progression of RA. In particular interstitial lung dise...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465816668780
更新日期:2017-01-01 00:00:00
abstract::One of the great challenges of lung transplantation is to bridge the dichotomy between supply and demand of donor organs so that the maximum number of potential recipients achieve a meaningful benefit in improvements in survival and quality of life. To achieve this laudable goal is predicated on choosing candidates wh...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466619880078
更新日期:2019-01-01 00:00:00